Clinical Trial

Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This clinical trial studies contrast enhanced spectral mammography (CESM) for the evaluation of pathologic nipple discharge. CESM is similar to standard mammography, but it includes an intravenous (by vein) injection of an iodine-based contrast, which makes tissue and blood vessels more visible in scans. The goal of this trial is to learn if CESM, is better than standard mammography in quickly and efficiently determining the cause of nipple discharge and detecting breast cancer, if present. CESM may increase the chance of finding breast cancers and lower the risk of having unnecessary biopsies.
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-12
notable Enrollment reduced: 66 -> 40 participants 2026-08-12
Trial Details
NCT Number NCT05056844
Lead Sponsor M.D. Anderson Cancer Center
Conditions Breast Carcinoma
Enrollment 40 participants
Start Date 2021-04-15
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11